Literature DB >> 1394098

Temporal association of marrow eosinophilia with inversion of chromosome 16 in recurrent blast crises of chronic myelogenous leukemia.

J P Evers1, A Bagg, E Himoe, J A Zwiebel, R J Jacobson.   

Abstract

We report a patient with Ph+ chronic myelogenous leukemia (CML) whose recurrent blast crises were associated with marrow eosinophilia and inv(16). After intensive chemotherapy, for each blast crisis, the patient reentered chronic phase with disappearance of both the inv(16) and the eosinophilia.

Entities:  

Mesh:

Year:  1992        PMID: 1394098     DOI: 10.1016/0165-4608(92)90251-3

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  4 in total

1.  Inversion of chromosome 16 in accelerated phase of chronic myeloid leukaemia: report of a case and review of the literature.

Authors:  M Colović; G Janković; J Bila; V Djordjević; P H Wiernik
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

2.  Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Authors:  Alireza Salem; Sanam Loghavi; Guilin Tang; Yang O Huh; Elias J Jabbour; Hagop Kantarjian; Wei Wang; Shimin Hu; Rajyalakshmi Luthra; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Am J Hematol       Date:  2017-04-06       Impact factor: 10.047

Review 3.  Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis.

Authors:  Soranobu Ninomiya; Nobuhiro Kanemura; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Toshiki Yamada; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2011-04-27       Impact factor: 2.490

4.  Coexistence of p210BCR-ABL and CBFβ-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.

Authors:  Yuan-Yuan Wang; Wen-Jing Ding; Feng Jiang; Zi-Xing Chen; Jian-Nong Cen; Xiao-Fei Qi; Jian-Ying Liang; Dan-Dan Liu; Jin-Lan Pan; Su-Ning Chen
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.